Clinical Trial Update: A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients

View source ↗

Summary

A completed real-world study assessing the effectiveness of inclisiran and PCSK9 monoclonal antibodies in Chinese adults with hypercholesterolemia and mixed dys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Evolocumab (evolocumab)
• Inclisiran (inclisiran)
• alirocumab (alirocumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypercholesterolemia, Mixed Dyslipidemia | Status: COMPLETED